VolitionRX Limited Common Stock (VNRX)

DALLAS, Texas, Nov. 13, 2026 - VivoSim Labs, Inc. (Nasdaq: VIVS) and Chemveda Life Sciences are moving human-tissue testing earlier in AI-driven drug development. Chemveda designs and synthesizes AI-generated molecules, while VivoSim evaluates their safety, efficacy and mechanism in 3D human liver and intestinal tissue while the compounds can still be redesigned. That timing addresses a central risk of generative drug discovery: its most promising molecules are often entirely new, meaning no human liver or intestine has encountered them before.

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that it has signed a nonbinding letter of intent (“LOI”) with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology (“LFT”) for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating the finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings. Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries and other institutions, could support low-cost manufacturing, clinical studies and distribution.

VolitionRx Limited (NYSE American: VNRX) announced the official launch of the DETECSEPS project for the early detection of sepsis as part of the DETECSEPS Consortium, which is receiving €6.3 million, or approximately $7.3 million, in French government funding. The project is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique – Hôpitaux de Paris in partnership with Hospices Civils de Lyon, IDS France and Volition. Volition will provide the project’s sole biomarker, Nu.Q NETs, while IDS France will provide its automated analyzer to measure the biomarker.

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed paper reporting that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. Published in Critical Care Medicine, the study found significantly higher Nu.Q NETs H3.1 levels in septic shock patients than in sepsis patients and a dose-response relationship with acute kidney injury severity, supporting its potential use for risk stratification and early intervention. The journal also published an independent editorial examining H3.1 nucleosomes as a potential marker of NET-mediated organ injury.

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that results using its lateral flow finger-prick prototype were highly correlated with results from its established automated Nu.Q NETs test in critically ill sepsis patients, supporting the potential expansion of nucleosome testing beyond centralized laboratories. The company said the lateral flow test could enable rapid identification of high-risk patients in emergency rooms or at the bedside, with testing showing a Spearman correlation of 0.85 and Pearson correlation of 0.881 compared with its CE-marked laboratory assay.

VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (“ctDNA”). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.

VolitionRx Limited (NYSE American: VNRX) highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis, while releasing an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. The company said multiple studies have shown its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity and provide strong prognostic value for outcomes including organ failure and mortality.

VolitionRx Limited (NYSE American: VNRX) announced the release of a new clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted with researchers and clinicians at France’s Hospices Civils de Lyon, the real-world study found that levels of the assay’s H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival, while a prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. The paper is currently under peer review.

VolitionRx Limited (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.

VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company’s existing Nu.Q(R) NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.

VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies.

VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, achieving 97% specificity and identifying 86% of cases, advancing development of a blood-based liquid biopsy test for feline cancer.

VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples. The findings also support the feasibility of early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.

VolitionRx (NYSE American: VNRX) announced proof-of-concept data from a blinded validation cohort demonstrating over 95% sensitivity for stage I and II cancers with 95% specificity using its Capture-Seq liquid biopsy technology. The study, which included 81 subjects, showed detection rates of 94% for stage I and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%, highlighting the technology’s potential for early cancer detection.

VolitionRx (NYSE American: VNRX) announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its Capture-Seq(TM) platform, overcoming a longstanding challenge of distinguishing cancer DNA from healthy cell-free DNA in blood samples. The company reported strong early validation results, including no false positives and successful detection across initial study cohorts, supporting the potential of the technology as a novel biomarker approach.

VolitionRx (NYSE American: VNRX) announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan, enabling full automation in central laboratories through the IDS i10 automated analyzer platform. The company said the transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows, with more than 1,700 veterinary hospitals in Japan already registered to use the test. Volition highlighted Japan’s approximately seven million pet dogs and noted the automated platform aligns with the same system used for its human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, provided a consolidated update highlighting recent clinical and commercial progress across its key platforms.

VolitionRx (NYSE American: VNRX), a multi-national epigenetics company, announced the appointment of Medical & Biological Laboratories Co. Ltd. as a non-exclusive distributor of its Nu.Q(R) Discover assays in Japan. The agreement expands access to Volition’s nucleosome-based biomarker assays for drug developers and researchers in the Japanese market and builds on the Company’s growing global collaborator network, as Nu.Q(R) Discover now serves close to 100 clients worldwide, including leading pharmaceutical and diagnostic companies using the assays to support disease research, drug development, and late-stage clinical trials.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by Hospices Civils de Lyon, France’s second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL.

VolitionRx (NYSE American: VNRX), a multinational epigenetics company, announced results from a clinical study demonstrating high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, meaning no false positives, the blood-based assay detected more than 80% of feline lymphomas, supporting development of what the company expects to be the world’s first simple and affordable liquid biopsy test for feline cancer.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced the preprint release of research introducing Capture-Seq(TM), a new method for analyzing transcription factor–protected ultrashort DNA fragments in blood as potential low-cost cancer biomarkers. The manuscript, titled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq,” highlights Volition’s achievement of 180-fold enrichment of transcription factor–bound fragments by focusing on DNA in its natural chromosomal context rather than on chemically extracted DNA, overcoming the longstanding challenge of overwhelming background DNA in liquid biopsy testing.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that its Nu.Q® NETs H3.1 assay has been chosen as the sole biomarker for “DETECSEPS,” a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million (~$7.3 million) grant, aims to transform emergency care for patients with infection and risk of sepsis progression.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc. (NASDAQ: HOLX), to promote Volition’s Nu.Q® Discover service. The program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen’s Immunoassay Technology Center to assess antiphospholipid syndrome (“APS”) using Volition’s Nu.Q H3.1 Neutrophil Extracellular Traps (“NETs”) assay on Werfen platforms.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com